🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 6 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 11/09/2006 | 35,19 | 35,38 | 34,13 | 34,82 | -1,47% | 3,55% | 804.600 |
| 08/09/2006 | 34,80 | 35,53 | 34,75 | 35,34 | +1,73% | 2,24% | 1.025.200 |
| 07/09/2006 | 34,85 | 35,42 | 34,11 | 34,74 | -0,20% | 3,76% | 833.300 |
| 06/09/2006 | 36,15 | 36,20 | 34,66 | 34,81 | -3,71% | 4,26% | 965.900 |
| 05/09/2006 | 36,34 | 36,50 | 35,79 | 36,15 | -0,17% | 1,95% | 853.900 |
| 01/09/2006 | 34,63 | 36,31 | 34,62 | 36,21 | +5,11% | 4,88% | 1.419.100 |
| 31/08/2006 | 35,67 | 35,67 | 34,39 | 34,45 | -1,52% | 3,59% | 1.079.500 |
| 30/08/2006 | 34,60 | 35,01 | 34,31 | 34,98 | +1,19% | 2,02% | 1.045.900 |
| 29/08/2006 | 34,86 | 35,15 | 34,37 | 34,57 | -1,09% | 2,24% | 1.267.000 |
| 28/08/2006 | 35,34 | 35,56 | 34,88 | 34,95 | -1,35% | 1,92% | 972.600 |
| 25/08/2006 | 33,34 | 35,74 | 32,91 | 35,43 | +9,83% | 8,49% | 2.163.600 |
| 24/08/2006 | 32,83 | 33,02 | 32,04 | 32,26 | -1,47% | 2,99% | 442.600 |
| 23/08/2006 | 32,87 | 32,87 | 32,44 | 32,74 | +0,09% | 1,31% | 691.200 |
| 22/08/2006 | 32,45 | 32,99 | 32,25 | 32,71 | +1,14% | 2,28% | 540.900 |
| 21/08/2006 | 32,43 | 33,10 | 32,04 | 32,34 | -1,13% | 3,27% | 718.300 |
| 18/08/2006 | 32,79 | 32,94 | 32,00 | 32,71 | +0,00% | 2,87% | 558.300 |
| 17/08/2006 | 32,32 | 32,94 | 32,00 | 32,71 | +1,36% | 2,91% | 656.600 |
| 16/08/2006 | 31,85 | 32,34 | 31,74 | 32,27 | +2,22% | 1,88% | 711.900 |
| 15/08/2006 | 31,35 | 31,74 | 30,60 | 31,57 | +3,07% | 3,64% | 693.700 |
| 14/08/2006 | 30,82 | 31,50 | 30,54 | 30,63 | +0,79% | 3,11% | 609.300 |
| 11/08/2006 | 30,49 | 30,71 | 30,05 | 30,39 | -0,16% | 2,16% | 769.000 |
| 10/08/2006 | 30,05 | 30,97 | 29,75 | 30,44 | +1,06% | 4,06% | 1.227.300 |
| 09/08/2006 | 30,88 | 31,36 | 29,88 | 30,12 | -1,54% | 4,79% | 1.034.800 |
| 08/08/2006 | 31,76 | 31,78 | 30,29 | 30,59 | -3,41% | 4,69% | 1.462.400 |
| 07/08/2006 | 32,28 | 32,28 | 31,55 | 31,67 | -1,86% | 2,26% | 887.600 |
| 04/08/2006 | 32,88 | 33,66 | 31,94 | 32,27 | -1,31% | 5,23% | 910.000 |
| 03/08/2006 | 32,06 | 32,87 | 31,59 | 32,70 | +1,08% | 3,99% | 1.040.600 |
| 02/08/2006 | 32,73 | 33,05 | 32,19 | 32,35 | -0,49% | 2,63% | 1.124.600 |
| 01/08/2006 | 33,23 | 33,44 | 32,05 | 32,51 | -3,01% | 4,18% | 1.004.100 |
| 31/07/2006 | 34,11 | 34,13 | 32,89 | 33,52 | -2,13% | 3,64% | 1.231.600 |